[
  {
    "ts": "2026-02-13T11:52:00+00:00",
    "headline": "Meet the 6.3% Yield Dividend Stock That Could Soar in 2026",
    "summary": "Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.",
    "url": "https://www.fool.com/investing/2026/02/13/meet-the-63-yield-dividend-stock-that-could-soar/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "9131a1d2-b50f-3443-a9af-b546aac2f63e",
      "content": {
        "id": "9131a1d2-b50f-3443-a9af-b546aac2f63e",
        "contentType": "STORY",
        "title": "Meet the 6.3% Yield Dividend Stock That Could Soar in 2026",
        "description": "",
        "summary": "Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.",
        "pubDate": "2026-02-13T11:52:00Z",
        "displayTime": "2026-02-13T11:52:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/0ff27e1a71595f51622eeced0f48f02c",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "A tape measure with a pile of pills.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nc3iEXmggYfhLqLFrYtmWQ--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/0ff27e1a71595f51622eeced0f48f02c.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NGml6BOPwYodldRXME78UQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/0ff27e1a71595f51622eeced0f48f02c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/02/13/meet-the-63-yield-dividend-stock-that-could-soar/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/meet-6-3-yield-dividend-115200735.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T15:13:33+00:00",
    "headline": "Pfizer Obesity And Hemophilia Advances Spark Fresh Interest In Valuation",
    "summary": "Pfizer reported positive Phase 2b results for its monthly GLP-1 obesity drug candidate PF-3944, with plans to run more than 20 clinical trials, including several focused on this asset. The FDA granted Priority Review for expanded use of HYMPAVZI in hemophilia A or B, potentially widening its eligible patient pool. These updates highlight fresh developments in obesity and hematology that go beyond routine product updates or earnings headlines. For investors tracking NYSE:PFE, these pipeline...",
    "url": "https://finance.yahoo.com/news/pfizer-obesity-hemophilia-advances-spark-151333990.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "ddb0adf9-72e9-326b-acca-ab76db2c477f",
      "content": {
        "id": "ddb0adf9-72e9-326b-acca-ab76db2c477f",
        "contentType": "STORY",
        "title": "Pfizer Obesity And Hemophilia Advances Spark Fresh Interest In Valuation",
        "description": "",
        "summary": "Pfizer reported positive Phase 2b results for its monthly GLP-1 obesity drug candidate PF-3944, with plans to run more than 20 clinical trials, including several focused on this asset. The FDA granted Priority Review for expanded use of HYMPAVZI in hemophilia A or B, potentially widening its eligible patient pool. These updates highlight fresh developments in obesity and hematology that go beyond routine product updates or earnings headlines. For investors tracking NYSE:PFE, these pipeline...",
        "pubDate": "2026-02-13T15:13:33Z",
        "displayTime": "2026-02-13T15:13:33Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-obesity-hemophilia-advances-spark-151333990.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-obesity-hemophilia-advances-spark-151333990.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-13T14:57:35+00:00",
    "headline": "Is Pfizer Inc. (PFE) One of the Best Medical Research Stocks to Buy According to Hedge Funds?",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the best medical research stocks to buy according to hedge funds. Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority Review for its supplemental Biologics License Application for HYMPAVZI® for the expansion of the approved indication to include treatment of […]",
    "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-one-best-145735771.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "d1626b07-9a75-3e04-8fac-3efc4f384c05",
      "content": {
        "id": "d1626b07-9a75-3e04-8fac-3efc4f384c05",
        "contentType": "STORY",
        "title": "Is Pfizer Inc. (PFE) One of the Best Medical Research Stocks to Buy According to Hedge Funds?",
        "description": "",
        "summary": "Pfizer Inc. (NYSE:PFE) is one of the best medical research stocks to buy according to hedge funds. Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority Review for its supplemental Biologics License Application for HYMPAVZI® for the expansion of the approved indication to include treatment of […]",
        "pubDate": "2026-02-13T14:57:35Z",
        "displayTime": "2026-02-13T14:57:35Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Pfizer (PFE) Closes 2025 on Solid Note, Returns $9.8B to Shareholders",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UKiv8LHLxutAA7dDIzr_pw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1v0rnd.QZj0de1gLzaNuAg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/aef4b35e5ea946bf7f4ed347e5c4f487.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-one-best-145735771.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-inc-pfe-one-best-145735771.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]